A process for making an intraocular implant, the process comprising the steps of: (a) combining: (i) a cyclic lipid therapeutic agent that is a prostaglandin, prostaglandin analog, prostamide, or prostamide analog; (ii) a first biodegradable polymer, and; (iii) a second biodegradable polymer to form a mixture, wherein; (α) the first biodegradable polymer and the second biodegradable polymer are different polymers; (β) the solubilities of the cyclic lipid therapeutic agent, the first biodegradable polymer, and the second biodegradable polymer are all within 10 MPa 1⁄2 of each other, and; (γ) the melt temperature of the second biodegradable polymer is between 50°C and 80°C and is lower than the melt transition temperature of the first biodegradable polymer, (b) heating the mixture to the lower melt temperature of the second biodegradable polymer, so that the second biodegradable polymer can function as a solvent for the cyclic lipid therapeutic agent and for the first biodegradable polymer, wherein the melt temperature of the second biodegradable polymer is lower than the temperature at which the cyclic lipid therapeutic agent exhibits a substantial loss of potency, and; (c) extruding the heated mixture, thereby making an implant suitable for intraocular use. (a) combining: (i) a cyclic lipid therapeutic agent that is a prostaglandin, prostaglandin analog, prostamide, or prostamide analog; (ii) a first biodegradable polymer, and; (iii) a second biodegradable polymer to form a mixture, wherein; (α) the first biodegradable polymer and the second biodegradable polymer are different polymers; (β) the solubilities of the cyclic lipid therapeutic agent, the first biodegradable polymer, and the second biodegradable polymer are all within 10 MPa 1⁄2 of each other, and; (γ) the melt temperature of the second biodegradable polymer is between 50°C and 80°C and is lower than the melt transition temperature of the first biodegradable polymer, (i) a cyclic lipid therapeutic agent that is a prostaglandin, prostaglandin analog, prostamide, or prostamide analog; (ii) a first biodegradable polymer, and; (iii) a second biodegradable polymer to form a mixture, wherein; (α) the first biodegradable polymer and the second biodegradable polymer are different polymers; (β) the solubilities of the cyclic lipid therapeutic agent, the first biodegradable polymer, and the second biodegradable polymer are all within 10 MPa 1⁄2 of each other, and; (γ) the melt temperature of the second biodegradable polymer is between 50°C and 80°C and is lower than the melt transition temperature of the first biodegradable polymer, (α) the first biodegradable polymer and the second biodegradable polymer are different polymers; (β) the solubilities of the cyclic lipid therapeutic agent, the first biodegradable polymer, and the second biodegradable polymer are all within 10 MPa 1⁄2 of each other, and; (γ) the melt temperature of the second biodegradable polymer is between 50°C and 80°C and is lower than the melt transition temperature of the first biodegradable polymer, (b) heating the mixture to the lower melt temperature of the second biodegradable polymer, so that the second biodegradable polymer can function as a solvent for the cyclic lipid therapeutic agent and for the first biodegradable polymer, wherein the melt temperature of the second biodegradable polymer is lower than the temperature at which the cyclic lipid therapeutic agent exhibits a substantial loss of potency, and; (c) extruding the heated mixture, thereby making an implant suitable for intraocular use.